What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher

View Full Paper

Ask AI

Bookmark

Authors

Phase II study demonstrates blinatumomab enhances MRD-negativity in adults with B-cell ALL, suggesting improved outcomes through ASCT.

Blinatumomab achieved a 73% MRD response rate after 4 cycles of treatment, with 65% of patients achieving MRD-negativity after Cycle 1.
Next generation sequencing revealed that 3 of 5 patients reached MRD-negativity at a 10-6 threshold, indicating effective minimal residual disease monitoring.
Allogeneic stem cell transplantation was undertaken by 33% of responders after treatment, supporting its role in long-term management.
Overall survival at 5 years was estimated at 60%, with notable improvements for patients achieving MRD <10-3.

Rausch et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase II study demonstrates blinatumomab enhances MRD-negativity in adults with B-cell ALL, suggesting improved outcomes through ASCT.

Blinatumomab achieved a 73% MRD response rate after 4 cycles of treatment, with 65% of patients achieving MRD-negativity after Cycle 1.
Next generation sequencing revealed that 3 of 5 patients reached MRD-negativity at a 10-6 threshold, indicating effective minimal residual disease monitoring.
Allogeneic stem cell transplantation was undertaken by 33% of responders after treatment, supporting its role in long-term management.
Overall survival at 5 years was estimated at 60%, with notable improvements for patients achieving MRD <10-3.

Rausch et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark